The FDA declares that there is no hay vinculo between Johnson & Johnson’s vacuano and the cases of blood thistles

The Food and Drug Administration (FDA) Administration indicates that these four at the moment there is no causal relationship between the vaccine and the covid-19 of the Johnson & Johnson pharmaceuticals and the cases of people suffering from blood clots.

“At the moment, we have not found any causal relationship with the vacancy and we are continuing our investigation and analysis of these cases”, indicates in a statement the regulator.

The FDA is reviewing the information about “some individuals” who are suffering from platelets and low plaque levels in the blood transfusion.

“Both conditions can have different causes”, asafuró la FDA. “We will keep the public informed in the media that we have more data”, agreed.

The European Medicines Agency (EMA) indicates that these firms are investigating a possible angle on the composition of J&J and cases of coagulation. “A case is being produced in a clinical setting and three are being produced during the evacuation in the United States. One of those deadly forces, ”the EMA indicated.

The FDA signals that the European Agency’s communication is based on its information.

The J&J vaccine is administered at a dose authorized for use in the United States in February finals after that the regulator would put green on the immunizers of the pharmaceuticals Pfizer / BioNTech and Moderna.

Problems with manufacturing in Baltimore

For another lad, next week Johnson & Johnson will reduce by 80% the number of vacancies that will be included in the EUEU after the problems of production registered in a Baltimore plant. According to figures from the Centers for Disease Control and Prevention (CDC, in English), the federal governor has assigned only 700,000 J&J vacancies to the distant states of the country, a figure that is drastically lower than the 4.9 million this week.

The descent complicates the massive evacuation campaign that is taking place in the EU, while the number of candidates to receive the dose is constantly increasing, since in more than 30 states he opened the vacancies to all the major adults of 16 years.

It is to be hoped that J&J will issue a semi-annual dose relatively soon enough to obtain authorization from the EU authorities of a Baltimore plant production company that has been experiencing problems, confirming its release at a press release Response to Covid-19 from Casa Blanca, Jeff Zients.

To appear, in the installations, belonging to the firm Emergent BioSolutions, are “accidentally” mentioned in mediocre marzo constituents of the vacuum of J&J and AstraZeneca, which malogró has up to 15 million of Johnson & Johnson dose and has forced the regulatory authorities to withdraw the authorization of the production lines of the factory.

The same plant produces as many doses of J & J’s formula as the AstraZeneca pharmaceutical, intended to combat covid-19.

The European Union’s embarrassing problems do not affect the European Union, since this region uses a EUSR Independent Member’s case.

With AFP information on EFE

SEGUIR LEYENDO: